Date: November 13, 2026.

To,

Asst. General Manager,
Dept. of Corporate Services,
BSE Limited
1st Floor, P.J. Towers,
Dalal Street, Fort,
Mumbai: 400001.

Sub: Outcome of the Board Meeting held on November 13, 2026.
Reference: CLINITECH LABORATORY LIMITED (CTLLAB) Scrip Code: 544220.

We hereby inform that the Board of Directors of the company, at its meeting held today i.e., November 13, 2026, have:

- Approved the Un-Audited Standalone & Consolidated Financial Result of the Company along with Limited Review Report (LRR) for the half year ended September 30, 2026;
- Considered and noted utilization of IPO Proceeds
- Took note of Internal Audit report for the half year ended September 30, 2026.

In connection with Point No. 1, please find enclosed the copy of Un-Audited Standalone & Consolidated financial Results of the Company along with Limited Review Report (LRR) for the half year ended September 30, 2026 by the Statutory Auditors of the Company as ***"Annexure-I"*** and copy of certificate indicating the utilization of the issue proceeds certified by Statutory Auditor as required pursuant to circular no. NSE/CML/2024/23 as ***'Annexure – II'***

The meeting commenced at 12.00 Noon (IST) and concluded at 01.00 P.M (IST)

Kindly take the note of the above.

Thanking you,
Yours faithfully,
For CLINITECH LABORATORY LIMITED

JAGDISH UMAKANT NAYAK
Digitally signed by JAGDISH UMAKANT NAYAK
Date: 2026.11.13 13:16:34 +05'30'

Jagdish Umakant Nayak
Chairman and Managing Director
DIN: 00646672
Encl: as above

Kale Malde & Co.
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivli (East)- 421 201
Mob: 9821292688 /8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

Independent Auditor's Limited Review Report on Unaudited Standalone Financial Results for the Half Year ended on 30th September, 2026 of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
Clinitech Laboratory Limited
AL 1 545/546, sec 16 Airoli,
Opp. Smt. Radhikabai Meghe Vidyalaya,
Navi Mumbai - 400 708

Dear Sir,

Re: Limited Review Report of the Unaudited Standalone Financial Results for the Half Year ended 30th September 2026

We have reviewed the accompanying statement of unaudited standalone financial results of Clinitech Laboratory Limited ("the Company") for the Half year ended 30th September 2026 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Management's Responsibility

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25, "Interim Financial Reporting" (AS 25), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

Scope of Review

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

KALE MALDE & CO
DOMBIVALI
FRN:154422W
CHARTERED ACCOUNTANTS

Kale Malde & Co.
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivli (East)- 421 201
Mob: 9821292688 /8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results, prepared in accordance with applicable Accounting Standards specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s KALE MALDE & CO.
(Chartered Accountants)
Reg No. :0154422W

KALE MALDE & CO. DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

(CA. Alpesh Malde)
Partner
M.No. : 138034
Date: 13/11/2026
Place : Dombivli
ICAI UDIN: 26138034AFWOHR2603

CLINITECH LABORATORY LIMITED
CIN : L85195MH2010PLC201078
Unaudited Statement of Standalone Assets and Liabilities as at 30th September 2026

All amounts in Lakhs, unless otherwise stated

Particulars	As at September 30, 2026	As at March 31, 2026
I. EQUITY AND LIABILITIES		
Shareholders' funds		
Share capital	228.24	228.24
Reserves and Surplus	721.51	697.04
	949.75	**925.28**
Non-current liabilities		
Long-Term Borrowings	86.44	35.76
Long-Term Provisions	25.10	25.34
	111.54	**61.10**
Current liabilities		
Trade Payables		
total outstanding dues of micro and small enterprises	35.35	26.40
total outstanding dues of creditors other than micro and small enterprises	18.99	13.55
Other current liabilities	47.46	43.44
Short-Term Provisions	30.67	21.61
	132.47	**105.00**
TOTAL EQUITY AND LIABILITIES	**1193.76**	**1091.39**
II. ASSETS		
Non-current assets		
Property, Plant and Equipment and Intangible Assets		
Property, Plant and Equipment	267.62	214.35
Intangible assets	2.80	3.99
Intangible Assets under development	99.33	99.12
Non-current investments	8.49	8.49
Other Non-current assets	18.61	9.18
Deferred Tax Assets (Net)	18.97	19.92
	415.82	**355.05**
Current assets		
Inventories	76.37	73.05
Trade Receivables	225.10	184.68
Cash and Cash Equivalents	187.20	206.46
Short-term loans and advances	65.76	69.53
Other current assets	223.51	202.62
	777.94	**736.34**
TOTAL ASSETS	**1193.76**	**1091.39**

As per our report of even date
For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 13/11/2026
Place: Dombivli
ICAI UDIN: 26138034AFWOHR2603

For and on behalf of the Board of Directors of
CLINITECH LABORATORY LIMITED

Jagdish Umakant Nayak
Chairman and Managing Director
DIN : 00646672
Date: 13/11/2026
Place: Navi Mumbai

CLINITECH LABORATORY LIMITED

CIN : L85195MH2010PLC201078

Statement of Unadudited Standalone Financial Results for the Half Year ended 30th September, 2026

All amounts in INR Lakhs, unless otherwise stated

Particulars	Half year Ended on			Year Ended on	
	30-Sep-26	31-Mar-26	30-Sep-25	31-Mar-26	31-Mar-25
	Unaudited	Audited	Unaudited	Audited	Audited
A] REVENUE					
Revenue from operations	549.32	439.48	508.02	947.50	823.49
Other income	2.50	7.81	11.00	18.81	22.77
B] Total Income	**551.82**	**447.29**	**519.02**	**966.31**	**846.26**
C] Expenses:					
Cost of Consumables Used	122.06	87.25	137.76	225.01	155.93
Laboratory Testing Charges	16.04	14.21	17.43	31.64	27.33
Employee benefits expense	165.82	151.18	157.18	308.36	286.14
Finance costs	2.99	2.18	4.74	6.92	5.51
Depreciation and Amortization Expense	30.07	25.99	25.05	51.04	44.98
Other Expenses	179.85	141.17	141.78	282.96	270.90
D] Total expenses	**516.83**	**421.98**	**483.94**	**905.93**	**790.79**
E] Profit before tax	**34.99**	**25.31**	**35.08**	**60.38**	**55.47**
F] Tax expense:					
(1) Current tax	9.58	11.55	4.68	16.23	15.96
(2) Excess/(Short) Provsion of Income tax	-	5.17	-	5.17	-
(3) Deferred tax	0.95	-3.64	0.37	-3.27	0.04
G] Total Tax Expenses	**10.53**	**13.08**	**5.05**	**18.13**	**16.00**
H] Profit/(Loss) After Tax [E - G]	**24.46**	**12.23**	**30.03**	**42.25**	**39.47**
Earning per equity share:					
Face value per equity shares Rs.10/- fully paid up.					
(1) Basic	1.07	0.59	1.32	1.85	1.90
(2) Diluted	1.07	0.59	1.32	1.85	1.90

As per our report of even date
For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 13/11/2026
Place: Dombivli
ICAI UDIN: 26138034AFWOHR2603

For & On Behalf of the Board
CLINITECH LABORATORY LIMITED

Jagdish Nayak
Chairman and Managing Director
DIN : 00646672
Date: 13/11/2026
Place: Navi Mumbai

CLINITECH LABORATORY LIMITED
CIN : L85195MH2010PLC201078
Unaudited Standalone Statement of Cash Flows for the Half year ended 30th September, 2026

All amounts in Lakhs, unless otherwise stated

Particulars	Half Year ended September 30, 2026	Year ended March 31, 2026
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	34.99	60.38
Adjustments for :		
Interest income	-0.56	-12.29
Interest expense	1.85	3.25
Depreciation and Amortization Expense	30.07	51.04
Operating Profit Before Working Capital Changes	**66.35**	**102.38**
Increase / (Decrease) in Trade Payables	14.39	-35.54
Increase / (Decrease) in Other liabilities	4.02	-31.01
Increase / (Decrease) in Short Term Provisions	9.05	-9.53
Increase / (Decrease) in Other Long Term Liabilities/ Provisions	-0.24	5.46
Decrease / (Increase) in Inventories	-3.32	-20.18
Decrease / (Increase) in Trade Receivables	-40.42	-30.58
Decrease / (Increase) in loans and advances	3.77	3.62
Decrease / (Increase) in Other assets	-20.90	-43.58
Decrease / (Increase) in Other Non-Current assets	-9.42	-9.18
Cash generated from / (used in) Operations	**23.29**	**-68.15**
Income taxes paid	-9.58	-21.40
Net Cash generated from / (used in) Operating Activities	**13.71**	**-89.55**
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment and Intangible Assets	-82.36	-57.08
Sale proceeds of Property, Plant and Equipment and Intangible Assets	-	2.00
Purchase of Non-current investments	-	-1.20
Interest received	0.56	12.29
Net Cash generated from / (used in) Investing Activities	**-81.80**	**-43.99**
C. CASH FLOW FROM FINANCING ACTIVITIES		
Procceds from Long-Term Borrowings	50.67	35.76
Interest paid	-1.85	-3.25
Net Cash generated from / (used in) Financing Activities	**48.82**	**32.52**
Net Increase / (Decrease) In Cash and Cash Equivalents	**-19.26**	**-101.02**
Cash and Cash Equivalents at the Beginning	206.46	307.48
Cash and Cash Equivalents at the End	**187.20**	**206.46**

This cash flow statement has been prepared as per 'Indirect Method' as prescribed by Accounting Standard-3 (revised) "Cash Flow Statements"

As per our report of even date
For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 13/11/2026
Place: Dombivli
ICAI UDIN: 26138034AFWOHR2603

For and on behalf of the Board of Directors of
CLINITECH LABORATORY LIMITED

Jagdish Umakant Nayak
Chairman and Managing Director
DIN : 00646672
Date: 13/11/2026
Place: Navi Mumbai

Notes to the Financial Results:

1. The unaudited financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 13th November 2026.
2. As required under Regulation 33 of SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Reports on the unaudited financial results for the half-year ended on 30th September 2026 results were also approved by the Audit Committee and the Board of Directors at their meeting held on 13th November, 2026.
3. Earnings per Share (EPS) has been computed in accordance with Accounting Standard (AS) 20 – *Earnings Per Share*.
4. The Company is engaged in a single segment of Pathology and healthcare business. Therefore, segment-wise reporting as per Accounting Standard (AS) 17 – *Segment Reporting* is not applicable.
5. As per MCA Notification dated 16th February 2015, companies listed on the SME Exchange, as referred to in Chapter XB of SEBI (ICDR) Regulations, 2009, are exempt from the mandatory adoption of Ind-AS. Accordingly, the Company has not adopted Ind-AS for preparation of these financial results.
6. The comparative financial information for the half-year ended 30th September 2026 has been presented. The management has exercised due diligence to ensure that such information presents a true and fair view.
7. Figures of the previous period/year have been regrouped or reclassified wherever necessary to make them comparable with the current period's figures.
8. The Standalone Financial results are available on the website of the Company and the website of the stock exchange where the shares of the company are listed.

CLINITECH LABORATORY LIMITED

KALE MALDE & CO DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

Kale Malde & Co.
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 /8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

Independent Auditor's Limited Review Report on Unaudited Consolidated Financial Results for the Half Year ended on 30th September, 2026 of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
Clinitech Laboratory Limited
AL 1 545/546, sec 16 Airoli,
Opp. Smt. Radhikabai Meghe Vidyalaya,
Navi Mumbai - 400 708

Dear Sir,

Re: Limited Review Report of the Consolidated Unaudited Financial Results for the Half Year ended 30th September 2026

We have reviewed the accompanying statement of consolidated unaudited financial results of Clinitech Laboratory Limited ("the Holding Company") and its subsidiaries (together referred to as "the Group") for the Half year ended 30 September 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended,

Management's Responsibility

The preparation of the consolidated statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, is the responsibility of the management

Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial results consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

KALE MALDE & CO
DOMBIVALI
FRN:154422W
CHARTERED ACCOUNTANTS

Kale Malde & Co.
Chartered Accountants

1, Shivkrupa Building
Patharli Road, Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 /8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable Accounting Standards specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Kale Malde & Co.
Chartered Accountants
Reg No. :0154422W

KALE MALDE & CO
DOMBIVALI
FRN:154422W
CHARTERED ACCOUNTANTS

CA Alpesh Malde
Partner
M.No.: 138034
Date: 13/11/2026
Place: Dombivli
ICAI UDIN: 26138034AIRMXW2713

CLINITECH LABORATORY LIMITED
CIN : L85195MH2010PLC201078
Unaudited Statement of Consolidated Assets and Liabilities as at 30th September 2026

All amounts in Lakhs, unless otherwise stated

Particulars	As at September 30, 2026	As at March 31, 2026
I. EQUITY AND LIABILITIES		
Shareholders' funds		
Share capital	228.24	228.24
Reserves and Surplus	732.93	696.59
Minority Interest	8.41	0.49
	969.58	925.32
Non-current liabilities		
Long-Term Borrowings	308.20	53.75
Long-Term Provisions	25.10	25.34
	333.30	79.09
Current liabilities		
Short-Term Borrowings	7.14	-
Trade Payables		
total outstanding dues of micro and small enterprises	35.90	27.05
total outstanding dues of creditors other than micro and small enterprises	39.11	21.30
Other current liabilities	57.73	43.49
Short-Term Provisions	36.88	21.61
	176.76	113.46
TOTAL EQUITY AND LIABILITIES	1479.64	1117.87
II. ASSETS		
Non-current assets		
Property, Plant and Equipment and Intangible Assets		
Property, Plant and Equipment	359.64	214.35
Capital Work-in Progress	-	25.51
Intangible assets	2.80	3.99
Intangible Assets under development	99.33	99.12
Non-current investments	7.29	7.29
Other Non-current assets	19.53	10.23
Deferred Tax Assets (Net)	18.53	19.92
	507.12	380.41
Current assets		
Inventories	120.21	73.05
Trade Receivables	354.18	185.47
Cash and Cash Equivalents	197.45	211.22
Short-term loans and advances	64.67	65.01
Other current assets	236.01	202.71
	972.52	737.46
TOTAL ASSETS	1479.64	1117.87

As per our report of even date
For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 13/11/2026
Place: Dombivli
ICAI UDIN: 26138034AIRMXW2713

For and on behalf of the Board of Directors of
CLINITECH LABORATORY LIMITED

Jagdish Umakant Nayak
Chairman and Managing Director
DIN : 00646672
Date: 13/11/2026
Place: Navi Mumbai

CLINITECH LABORATORY LIMITED

CIN : L85195MH2010PLC201078

Statement of Unadudited Consolidated Financial Results for the Half Year ended 30th September, 2026

All amounts in INR Lakhs, unless otherwise stated

Particulars	Half year Ended on			Year Ended on	
	30-Sep-26	31-Mar-26	30-Sep-25	31-Mar-26	31-Mar-25
	Unaudited	Audited	Unaudited	Audited	Audited
A] REVENUE					
Revenue from operations	942.41	441.10	508.02	949.12	823.49
Other income	2.79	7.81	11.00	18.81	22.77
B] Total Income	**945.20**	**448.91**	**519.02**	**967.93**	**846.26**
C] Expenses:					
Cost of Consumables Used	406.26	88.42	137.76	226.18	155.93
Laboratory Testing Charges	16.04	14.21	17.43	31.64	27.33
Employee benefits expense	192.81	151.18	157.18	308.36	286.14
Finance costs	12.44	2.19	4.74	6.93	5.51
Depreciation and Amortization Expense	30.37	25.99	25.05	51.04	44.98
Other Expenses	225.85	142.38	141.78	284.17	270.90
D] Total expenses	**883.77**	**424.37**	**483.94**	**908.32**	**790.79**
E] Profit before tax	**61.43**	**24.54**	**35.08**	**59.61**	**55.47**
F] Tax expense:					
(1) Current tax	15.80	11.55	4.68	16.23	15.96
(2) Excess/(Short) Provsion of Income tax	-	5.17	-	5.17	-
(3) Deferred tax	1.39	-3.64	0.37	-3.27	0.04
G] Total Tax Expenses	**17.19**	**13.08**	**5.05**	**18.13**	**16.00**
H] Profit After Tax before Minority Interest [E - G]	**44.24**	**11.46**	**30.03**	**41.48**	**39.47**
Less/(Add): Minority Interest share in Profit/(Loss) of Subsidiaries	-7.91	0.31	-	0.31	-
Profit for the year attributable to owners of the Parent Company	36.33	11.77	30.03	41.79	39.47
Earning per equity share:					
Face value per equity shares Rs.10/- fully paid up.					
(1) Basic	1.59	0.52	1.32	1.83	1.90
(2) Diluted	1.59	0.52	1.32	1.83	1.90

As per our report of even date
For KALE MALDE & CO.
Chartered Accountants
ICAI F.R No. 154422W

KALE MALDE & CO. DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 13/11/2026
Place: Dombivli
ICAI UDIN:26138034AIRMXW2713

For & On Behalf of the Board
CLINITECH LABORATORY LIMITED

Jagdish Nayak
Chairman and Managing Director
DIN : 00646672
Date: 13/11/2026
Place: Navi Mumbai

CLINITECH LABORATORY LIMITED

CLINITECH LABORATORY LIMITED
CIN : L85195MH2010PLC201078
Unaudited Consolidated Statement of Cash Flows for the Half year ended 30th September, 2026

All amounts in Lakhs, unless otherwise stated

Particulars	Half Year ended September 30, 2026	Year ended March 31, 2026
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax	61.43	59.62
Adjustments for :		
Interest income	-0.85	-12.29
Interest expense	8.80	3.25
Depreciation and Amortization Expense	30.37	51.04
Operating Profit Before Working Capital Changes	**99.75**	**101.61**
Increase / (Decrease) in Trade Payables	26.66	-27.14
Increase / (Decrease) in Other liabilities	14.24	-30.96
Increase / (Decrease) in Short Term Provisions	15.27	-9.53
Increase / (Decrease) in Other Long Term Liabilities/ Provisions	-0.24	5.46
Decrease / (Increase) in Inventories	-47.16	-20.18
Decrease / (Increase) in Trade Receivables	-168.71	-31.37
Decrease / (Increase) in loans and advances	0.34	8.14
Decrease / (Increase) in Other asset:	-33.31	-43.68
Decrease / (Increase) in Other Non-Current assets	-9.29	-10.23
Cash generated from / (used in) Operations	**-102.44**	**-57.86**
Income taxes paid	-15.80	-21.40
Net Cash generated from / (used in) Operating Activities	**-118.24**	**-79.26**
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment and Intangible Assets	-149.17	-82.58
Sale proceeds of Property, Plant and Equipment and Intangible Assets	-	2.00
Interest received	0.85	12.29
Net Cash generated from / (used in) Investing Activities	**-148.32**	**-68.29**
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of Share capital	-	0.80
Procceds from Long-Term Borrowings	254.45	53.75
Procceds from Short-Term Borrowings	7.14	-
Interest paid	-8.80	-3.25
Net Cash generated from / (used in) Financing Activities	**252.78**	**51.30**
Net Increase / (Decrease) In Cash and Cash Equivalents	**-13.77**	**-96.26**
Cash and Cash Equivalents at the Beginning	211.22	307.48
Cash and Cash Equivalents at the End	**197.45**	**211.22**

This cash flow statement has been prepared as per 'Indirect Method' as prescribed by Accounting Standard-3 (revised) "Cash Flow Statements"

As per our report of even date
For Kale Malde & Co.
Chartered Accountants
FRN: 154422W

CA. Alpesh Malde
Partner
Membership No: 138034
Date: 13/11/2026
Place: Dombivli
ICAI UDIN: 26138034AIRMXW2713

For and on behalf of the Board of Directors of
CLINITECH LABORATORY LIMITED

Jagdish Umakant Nayak
Chairman and Managing Director
DIN : 00646672
Date: 13/11/2026
Place: Navi Mumbai

Notes to the Consolidated Financial Results:

1. The unaudited Consolidated Financial results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 13th November,2026.
2. As required under Regulation 33 of SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Reports on the unaudited financial results for the half-year ended 30th September 2026. These results were also approved by the Audit Committee and the Board of Directors at their meeting held on 13th November 2026.
3. The consolidated financial results include the financial performance of the holding company and its subsidiary, in accordance with Accounting Standard (AS) 21 – Consolidated Financial Statements, as notified under the Companies (Accounting Standards) Rules, 2006.
4. Earnings per Share (EPS) has been computed in accordance with Accounting Standard (AS) 20 – *Earnings Per Share*.
5. The Holding Company is primarily engaged in the single segment of pathology and healthcare business. Other business activities carried out by the subsidiaries are not material for separate reportable segment disclosure in accordance with Accounting Standard (AS) 17 – 'Segment Reporting'. Accordingly, separate segment information has not been furnished.
6. As per MCA Notification dated 16th February 2015, companies listed on the SME Exchange, as referred to in Chapter XB of SEBI (ICDR) Regulations, 2009, are exempt from the mandatory adoption of Ind-AS. Accordingly, the Company has not adopted Ind-AS for preparation of these Consolidated Financial results.
7. Figures of the previous period/year have been regrouped or reclassified wherever necessary to make them comparable with the current period's figures.
8. The Consolidated Financial results are available on the website of the Company and the website of the stock exchange where the shares of the company are listed.

CLINITECH LABORATORY LIMITED

KALE MALDE & CO
DOMBIVALI
FRN:154422W
CHARTERED ACCOUNTANTS

Kale Malde & Co
Chartered Accountants

1, Shivkrupa Building
Patharli Road,Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

To,
Clinitech Laboratory Limited
AL 1 545/546, sec 16 Airoli,
Opp. Smt. Radhikabai Meghe Vidyalaya,
Navi Mumbai - 400 708

Sub: Certificate of Utilization of IPO Funds for the period ending on 30th September 2026

Management's responsibility for the Statement:

1. The preparation of the information in terms of the requirements of Generally Accepted Accounting principle (GAAP) is the responsibility of the Management of M/s Clinitech Laboratory Limited including the preparation and maintenance of all accounting and other relevant supporting record. This responsibility includes the design, implementation and maintenance of internal control relevant to the preparation and presentation of the statement and applying an appropriate basis of preparation; and making estimates that are reasonable in the circumstances.

Practitioner's responsibility:

2. Pursuant to the requirements of the requirements for certification of fund utilization as stipulated by SEBI and BSE, as per applicable regulations, our responsibility to examine the books of accounts and other relevant documents / records of the applicant and to provide a reasonable assurance that the information declared in the Statement are is in accordance with the books of accounts maintained.

3. To conduct our examination of the Statement in accordance with the Guidance Note on Reports or Certificates for Special Purposes (Revised 2016) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.

4. To comply with the relevant applicable requirements of the Standard on Quality Control (SQC) 1, Quality Control for Firms that Perform Audits and Reviews of Historical Financial Information, and Other Assurance and Related Services Engagements.

KALE MALDE & CO
DOMBIVALI
FRN:154422W
CHARTERED ACCOUNTANTS

Kale Malde & Co
Chartered Accountants

1, Shivkrupa Building
Patharli Road,Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

Opinion

1. We have conducted our examination in accordance with the Guidance Note on Reports or Certificates for Special Purposes (Revised 2016) issued by the Institute of Chartered Accountants of India. The Guidance Note requires that we comply with the ethical requirements of the Code of Ethics issued by the Institute of Chartered Accountants of India.

2. This certificate has been issued the request of the company and based on the information and documents provided by the management and is meant solely for the purpose of bank finance as per attached Annexure.

Restriction on Use

This certificate is addressed and provided to the verify the statutory records and books accounts to Verify the utilization of IPO funds aligns with the purposes specified in the prospectus details given in Attached annexure. This certificate solely for the purpose of submission to BSE and should not be used by any other person or for any other purpose. Accordingly, we do not accept or assume any liability or duty of care for any other purpose or to any other person to whom this certificate is shown or into whose hands it may come without our prior consent in writing.

For M/s. Kale Malde & Co.
Chartered Accountants,
FRN - 0154422W

KALE MALDE & CO
DOMBIVALI
FRN:154422W
CHARTERED ACCOUNTANTS

CA Alpesh Malde
M. no. 138034
Date: 13/11/2026
Place: Dombivli
UDIN: 26138034PTIYNQ5274

Kale Malde & Co
Chartered Accountants

1, Shivkrupa Building
Patharli Road,Shelar Naka,
Dombivali (East)- 421 201
Mob: 9821292688 8692000600
E-mail: lbkco.kale@gmail.com
alpesh1804@gmail.com

Annexure A

We have examined the books of account and other relevant records/documents maintained by the company in connection with the utilization of proceeds of the Initial Public Offering (IPO) as stated in the Offer Document for issuing 6,02,400 equity shares of ₹10/- each at a premium of ₹86/- per share total Amounting to Rs. 5,78,30,400/-

As of 30th September 2026, the details of funds raised, and their application are as follows:

(Amount in Lakhs)

Sr. No.	Object as disclosed in the Offer Document	Amount disclosed in the Offer Document	Actual Utilised Amount	Unutilised Amount	Remarks
1	Expansion of Diagnostic Business	498.67	498.67	0.00	
2	General Corporate Purposes	41.33	41.33	0.00	
3	Issue Related Expenses	38.30	38.30	0.00	
	Total	578.30	578.30	0.00	

We certify that:

- The company has fully applied the IPO proceeds for the disclosed purposes as of 30th September 2026.

This certificate is issued as per the guidance provided in the relevant ICAI pronouncements for a special-purpose certificate and is intended solely for your information.

For M/s. Kale Malde & Co.
Chartered Accountants,
FRN - 0154422W

KALE MALDE & CO DOMBIVALI FRN:154422W CHARTERED ACCOUNTANTS

CA Alpesh Malde
M. no. 138034
Date: 13/11/2026
Place: Dombivli
UDIN: 26138034PTIYNQ5274